A $225 million venture fund -- the first exclusively aimed at emerging stem cell companies -- looks to line up its lead investors by the end of the year, possibly by the end of September.

Proteus Venture Partners plans to invest in 10 to 15 so-called regenerative medicine companies at $10 million to $20 million per investment, said Jeffrey Karan, senior partner with the Palo Alto firm.

Its investments could range from early-stage research straight out of academia to public companies with clinical trials, from Bay Area startups to international companies, and from embryonic stem cell innovations to cord blood technology, Karan said.   Read More...